Position in FTRE
as of Jun 30, 2026
· filed Aug 19, 2026
Position Value
$1,137,907
+$573,960 QoQ
Shares Held
65,397
+9.2% QoQ
Ownership
0.069%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#98
of 334 holders
Holding Since
Sep 2023
8 quarters on record
Voting authority
Sole 36%
Shared 0%
None 64%
Common Shares in FTRE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026MERCER GLOBAL ADVISORS INC /ADV holds $303,308,584 across 140 Biotechnology names. FTRE ranks #22 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | APGE |
Apogee Therapeutics, Inc.
|
941,283 | $124,936,492 | |
| 2 | CAPR |
Capricor Therapeutics, Inc.
|
802,732 | $19,329,786 | |
| 3 | ORMP |
Oramed Pharmaceuticals Inc.
|
3,810,540 | $18,328,697 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
30,705 | $15,252,094 | |
| 5 | INCY |
Incyte Corp
|
116,207 | $13,173,225 | |
| 6 | REGN |
Regeneron Pharmaceuticals, Inc.
|
20,126 | $12,549,366 | |
| 7 | EXEL |
Exelixis, Inc.
|
176,339 | $9,594,604 | |
| 8 | CORT |
Corcept Therapeutics Inc
|
102,823 | $8,940,459 |
All Filings in FTRE
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,137,907 | 65,397 | Shares | Sole | 2026-08-19 | |
| 2026-03-31 | $563,947 | 59,867 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $643,166 | 37,285 | Shares | Sole | 2026-02-18 | |
| 2025-09-30 | $301,427 | 35,799 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $117,226 | 23,730 | Shares | Sole | 2025-08-14 | |
| 2024-03-31 | $286,679 | 7,142 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 | $262,971 | 7,535 | Shares | Sole | 2024-02-15 | |
| 2023-09-30 | $206,248 | 7,214 | Shares | Sole | 2023-11-15 | |
| No filing history on record for this holder in this stock. | ||||||